Document is current
Any future updates will be listed below
-
Authors
Takamori, Shinkichi
Haratake, Naoki
Bhattacharya, Atrayee
Kikutake, Chie
Ozawa, Hiroki
Shigeta, Keisuke
Nakashoji, Ayako https://orcid.org/0000-0003-2443-6995
Isozaki, Hideko
Shimokawa, Mototsugu
Suyama, Mikita
Hashinokuchi, Asato
Takada, Kazuki
Toyokawa, Gouji
Yamada, Yuichi
Takenaka, Tomoyoshi
Taguchi, Kenichi
Yamaguchi, Masafumi
Yoshizumi, Tomoharu https://orcid.org/0000-0002-4497-1816
Hata, Aaron N. https://orcid.org/0000-0002-6127-318X
Kufe, Donald https://orcid.org/0000-0001-5743-8888
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA97098, CA282437, CA289134)
- License Information
-
More Information
Article History
Received: 27 September 2025
Accepted: 27 October 2025
First Online: 28 November 2025
Competing interests
: DK has equity interests in Genus Oncology. ANH has received grants/research support from Amgen, Blueprint Medicines, BridgeBio, Bristol-Myers Squibb, C4 Therapeutics, Eli Lilly, Novartis, Nuvalent, Pfizer, Roche/Genentech, and Scorpion Therapeutics; and has served as a compensated consultant for Engine Biosciences, Nuvalent, Oncovalent, TigaTx, and Tolremo Therapeutics. The other authors declare no conflicts of interest.
